pte20181115001 Medicine / Health, Research / Technology
Parkinson: Protein Blockade destroys pieces
Human Brain – Tests with USP13 molecules successfully performed in mice
Trembling hands: I'm hoping for a new treatment approach (Photo: pixelio.de, R.B)
Washington, DC (pte 001 / 15-11-2018 at 6:00 pm) – The researchers at the University of Georgetown Medical Center (GUMC) http://gumc.georgetown.edu can not only dissolve the protein specific to the alpha-synuclein brain in the brain of the Parkinson's, but also break down. Studies in mice and the human brain show: One of the reasons for these so-called Lewy bodies is that the molecule USP13 has removed all markers of alpha-synuclein that characterizes the destruction of these proteins.
Ubiquitin as a key
The results published by Human Molecular Genetics show that the blockage of USP13 in Parkinson's mice did not cause Lewy bodies but also prevented the transition. The label that removes USP13 is called ubiquitin. This symbolizes protein degradation of alpha-synuclein.
According to research director Xiaoguang Liu, the current study provides new evidence that USP13 can be a therapeutic goal for Parkinson's and other related disorders. Three types of motor disorders are associated with alpha-synuclein accumulation: Parkinson's disease, dementia with Lewy bodies, and many systems of atrophy.
At the beginning of the study, the team has been researching the human brain. They included eleven brains from Parkinson's disease patients and control groups for nine healthy subjects. Detections were made from four to twelve hours after death. The level of USP13 in Parkinson's disease was found to be significantly increased.
In the next step, Parkinson's mouse models showed that deactivation of the USP13 gene could improve ubiquitinin alpha-synuclein and, consequently, degradation. In addition, deactivation of USP13 prevented mice from causing neuronal death due to alpha-synuclein, as explained by senior author Charbel Moussa. Animals had advanced mechanical skills. Parkin protein levels increased and alpha-synuclein was distributed. In addition, the effect of the protein kinase inhibitor nilotinib improved. This drug is approved by the United States to treat certain forms of blood cancer.